Article
Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
Medical hypotheses - 1 Apr 2011
Zhu Jian, Zuo Jianling, Xu Qinian, Wang Xiuyun, Wang Zhong, Zhou Dai
Abstract excerpt
Gliomas are the most common human brain tumours and can be classified into four grades based on clinical and pathological criteria. A recent cancer genome-sequencing project revealed that more than 70% of low-grade gliomas bear mutations in one of two NAD(+)-dependent isocitrate dehydrogenase enzymes, namely, IDH1 and IDH2. Based on the findings that glioma-derived mutations in IDH1 can inhibit the catalytic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.